The startup has developed a synthetic drug carrier platform that utilizes nanotechnology to deliver drugs and nonviral genes to cells via synthetic nanocarriers for subcutaneous nanotherapy. This technology enhances the efficacy and safety of treatments for a variety of diseases by improving drug delivery precision.
Funding
$250K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current drug and gene delivery methods often lack precision, leading to systemic toxicity and reduced therapeutic efficacy, particularly in immunotherapy applications. Traditional delivery systems struggle to target specific cell populations, resulting in off-target effects and limiting the potential of advanced therapies.
Solution
SNC Therapeutics has developed a synthetic nanocarrier (SNC) platform designed to enhance targeted drug and nonviral gene delivery. These nanocarriers enable controlled delivery to diverse cell populations, improving transfection efficiency while minimizing toxicity and side effects. The platform facilitates scalable and versatile drug delivery, supporting rational immunotherapy approaches. By precisely targeting cells, SNC Therapeutics aims to improve the safety and effectiveness of treatments.
Target Audience
The primary target audience includes researchers and pharmaceutical companies focused on developing advanced immunotherapies and gene therapies that require precise and efficient drug delivery systems.
Features
- Synthetic nanocarriers for targeted drug and nonviral gene delivery
- Scalable and versatile platform adaptable to various therapeutic payloads
- Controlled delivery mechanisms to minimize off-target effects
- Enhanced transfection efficiency for improved gene therapy outcomes
- Reduced toxicity profiles compared to traditional delivery methods